Navigation Links
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
Date:4/3/2012

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference.  The annual AACR meeting is one of the largest national cancer conferences in the US, highlighting the most significant advances in all areas of cancer research.  It is being held this year from March 31 to April 4 at McCormick Place in Chicago, Il.

The specific presentation highlighted by the AACR is entitled: "Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine" by Dr. Diane Hale et al.  The abstract will be available for viewing Tuesday April 3rd from 8 AM to 12 PM.  The study examined patients from the controlled, randomized trial of AE37 for immunological response to the vaccine.  AE37 consists of a fragment of the HER2 protein modified by proprietary means to increase potency in generating a specific immune response to HER2 expressing cancer cells.  The key findings from the study are that patients receiving AE37 indeed developed a specific immune response as indicated by an increase in circulating T cells in their blood specific for the HER2 fragment as well as a positive skin test (delayed type hypersensitivity).  In addition, patients receiving AE37 demonstrated a reduction in T regulatory cells, which are know to be able to hamper an immune response.

The AACR press conference was held Monday April 2nd.  Dr. Hale gave a brief oral presentation of the study followed by a question and answer period.

"The finding that AE37 generates a specific immune response is consistent with the activity we've observed to date, suggesting that patients receivi
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. Generex Secures Commitments for $3.6M Capital Raise
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
8. Generex Provides Update on Spinout of Antigen Express
9. Generex Augments Cash Position With Sales of Non-Essential Assets
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... July 28, 2014 The National Model ... Muncie IN, is pleased to announce that it has ... Museum of the United States Air Force. , The ... process that concluded this spring with an on-site inspection ... OH museum. , The National Museum of the ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... epigenetic anticancer program at Pharmion ... inhibitors - ... Significant opportunity to explore combination epigenetic therapies, BOULDER, Colo. ... and MethylGene Inc. (TSX: MYG) today announced a,research collaboration for ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: ... increased more than,35% over the first quarter of 2007 ... for the same period in the previous year. ... compared to only,$24,374 in the first half of 2006. ...
... COLUMBIA, Md., Aug. 14 Martek Biosciences,Corporation announced that ... of fiscal 2007 on September 5, 2007, at approximately ... 4:45 p.m. EDT Martek,will hold a conference call to ... with investors. The call is expected to be approximately ...
Cached Biology Technology:Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... of mayfly in the southern Western Ghats, a mountain range ... the first time that any mayfly belonging to the genus ... The new species, called Labiobaetis soldani , "is named ... to the understanding of the Ephemeroptera of Palaearctic and Oriental ... the new mayfly in the Journal of Insect Science ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... The discovery by Uppsala University researchers of a previously ... ways brings new potential for early diagnosis of a ... the Web edition of the American journal Proceedings ... provide new knowledge of the cause of common diseases ...
... native fishes in the Pacific Northwest are threatened or ... are expended annually on researching their populations and on ... been directed toward to the impacts of habitat alteration, ... published in the March 2009 issue of BioScience ...
... Society for Clinical and Economic Aspects of Osteoporosis and ... scientific programme for the upcoming IOF WCO- ECCEO10, a ... May 5-8, 2010. Complete programme information, online ... www.iofwco-ecceo10.org . IOF WCO-ECCEO10 will offer ...
Cached Biology News:World Congress on Osteoporosis 2010 presents outstanding scientific program 2
...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: